-
Je něco špatně v tomto záznamu ?
Primary refractory multiple myeloma: a real-world experience with 85 cases
A. Jurczyszyn, A. Waszczuk-Gajda, JJ. Castillo, K. Krawczyk, M. Stork, L. Pour, L. Usnarska-Zubkiewicz, S. Potoczek, I. Hus, J. Davila Valls, P. Hari, S. Chhabra, M. Gentile, G. Mikala, G. Varga, CS. Chim, M. Fiala, R. Vij, N. Schutz, M. Rodzaj,...
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- autologní transplantace MeSH
- doba přežití bez progrese choroby MeSH
- lidé MeSH
- mnohočetný myelom * diagnóza terapie MeSH
- přežití bez známek nemoci MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- transplantace hematopoetických kmenových buněk * MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.
3rd Department of Internal Medicine Semmelweis University Budapest Hungary
Complejo Asistencial de Avila Avila Spain
Dana Farber Cancer Institute Harvard Medical School Boston MA USA
Department of Hematology Jagiellonian University Medical College Cracow Poland
Department of Hematology Oncology and Internal Medicine Warsaw Medical University Warsaw Poland
Department of Hematology Regional Specialistic Hospital Cracow Poland
Department of Internal Medicine Hematology and Oncology University Hospital Brno Czech Republic
Department of Internal Medicine Hospital Italiano de Buenos Aires Buenos Aires Argentina
Division of Hematology and Medical Oncology Queen Mary Hospital Hong Kong China
Division of Hematology Oncology Department of Medicine Medical College of Wisconsin Milwaukee WI USA
Hematology Unit of Cosenza Italy
John Theurer Cancer Center Hackensack University Medical Center Hackensack NJ USA
Maria Sklodowska Curie National Research Institute of Oncology Warsaw Poland
Medical University of Lublin Lublin Poland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019754
- 003
- CZ-PrNML
- 005
- 20210830101343.0
- 007
- ta
- 008
- 210728s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/10428194.2020.1788014 $2 doi
- 035 __
- $a (PubMed)32623944
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Jurczyszyn, Artur $u Department of Hematology, Jagiellonian University Medical College, Cracow, Poland
- 245 10
- $a Primary refractory multiple myeloma: a real-world experience with 85 cases / $c A. Jurczyszyn, A. Waszczuk-Gajda, JJ. Castillo, K. Krawczyk, M. Stork, L. Pour, L. Usnarska-Zubkiewicz, S. Potoczek, I. Hus, J. Davila Valls, P. Hari, S. Chhabra, M. Gentile, G. Mikala, G. Varga, CS. Chim, M. Fiala, R. Vij, N. Schutz, M. Rodzaj, A. Porowska, DH. Vesole, A. Druzd-Sitek, J. Walewski, AK. Nooka
- 520 9_
- $a This study determined whether 85 patients with multiple myeloma (MM) double-refractory to primary induction therapy with triplet regimens had a homogenous prognosis. The overall response rate (ORR) after the second-line therapy was 51%. Patients who proceeded to immediate autologous stem cell transplantation (ASCT) had better ORR than those who received conventional therapies (62% vs. 31%). The ORR for patients who had ASCT directly after the frontline therapy was higher than for those treated with other regimens as the second line therapy (91% vs. 45%) and offered ASCT as the third-line therapy (91% vs. 55%). The median progression-free survival (PFS) after the second-line therapy and median overall survival were 21.6 months and 35.6 months, respectively. ASCT after the second line treatment (HR = 0.24) was an independent predictor of PFS. Eligible patients with primary refractory MM achieve the most benefit from ASCT, also performed immediately after first line induction therapy.
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mnohočetný myelom $x diagnóza $x terapie $7 D009101
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a autologní transplantace $7 D014182
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Waszczuk-Gajda, Anna $u Department of Hematology, Oncology and Internal Medicine, Warsaw Medical University, Warsaw, Poland
- 700 1_
- $a Castillo, Jorge J $u Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Krawczyk, Katarzyna $u Department of Hematology, Jagiellonian University Medical College, Cracow, Poland
- 700 1_
- $a Stork, Martin $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic
- 700 1_
- $a Pour, Ludek $u Department of Internal Medicine, Hematology and Oncology, University Hospital, Brno, Czech Republic
- 700 1_
- $a Usnarska-Zubkiewicz, Lidia $u Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
- 700 1_
- $a Potoczek, Stanisław $u Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland
- 700 1_
- $a Hus, Iwona $u Medical University of Lublin, Lublin Poland
- 700 1_
- $a Davila Valls, Julio $u Complejo Asistencial de Avila, Avila, Spain
- 700 1_
- $a Hari, Parameswaran $u Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
- 700 1_
- $a Chhabra, Saurabh $u Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
- 700 1_
- $a Gentile, Massimo $u Hematology Unit of Cosenza, Italy
- 700 1_
- $a Mikala, Gabor $u Department of Hematology and Stem Cell Transplantation, South-Pest Central Hospital, National Institute of Hematology and Infectology, Budapest, Hungary
- 700 1_
- $a Varga, Gergely $u 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
- 700 1_
- $a Chim, Chor Sang $u Division of Hematology and Medical Oncology, Queen Mary Hospital, Hong Kong, China
- 700 1_
- $a Fiala, Mark $u Washington University School of Medicine, St. Louis, MS, USA
- 700 1_
- $a Vij, Ravi $u Washington University School of Medicine, St. Louis, MS, USA
- 700 1_
- $a Schutz, Natalia $u Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- 700 1_
- $a Rodzaj, Marek $u Department of Hematology, Regional Specialistic Hospital, Cracow, Poland
- 700 1_
- $a Porowska, Agnieszka $u Department of Oncology and Haematology, Central Clinical Hospital of the Ministry of the Interior, Warsaw, Poland
- 700 1_
- $a Vesole, David H $u John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
- 700 1_
- $a Druzd-Sitek, Agnieszka $u Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Walewski, Jan $u Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
- 700 1_
- $a Nooka, Ajay K $u School of Medicine, Emory University, Atlanta, GA, USA
- 773 0_
- $w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 61, č. 12 (2020), s. 2868-2875
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32623944 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101343 $b ABA008
- 999 __
- $a ok $b bmc $g 1690544 $s 1140200
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 61 $c 12 $d 2868-2875 $e 20200705 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
- LZP __
- $a Pubmed-20210728
